|
INTRODUCTION
Sleep disorders, such as insomnia, narcolepsy and restless leg syndrome, are becoming an increasing focus for pharmaceutical manufacturers.
Sanofi-Synthlabo is testimony to this with its insomnia drug Ambien (zolpidem), which now boasts blockbuster revenues. Different commercial
opportunities exist in each of the analyzed sleep disorders for competing pharmaceutical manufacturers of all sizes.
SCOPE OF THE REPORT
- Analysis of the key epidemiological data points across each major pharmaceutical market for insomnia, narcolepsy and restless leg syndrome
- In-depth profiles of the current leading compounds in each sleep disorder, including future growth strategies, off-label case studies and
R&D strategy
- Detailed coverage of the entire R&D pipelines for insomnia, narcolepsy and restless leg syndrome, including profiles of all leading
candidates
- Comprehensive opinion leader research to compliment strategic recommendations for both marketed and pipeline drugs
REPORT HIGHLIGHTS
The entry of Pfizer into the insomnia market will generate a huge change in the current market dynamics. To continue to grow at a rapid rate, the
market has to be driven through primary care physicians. The success of Pfizer in driving markets through primary care illustrates why Neurocrine
chose Pfizer as a development partner for indiplon Sanofi's Ambien will remain the market leader for the foreseeable future but its position will be
threatened by the launch of Estorra, coupled with the patent expiry of the original brand in 2006. The company must learn from the introduction of
other new versions of existing drugs in other CNS markets to maximize the potential of Ambien MR.
KEY REASONS TO BUY THIS REPORT
- Understand the epidemiological barriers to market growth in each highlighted sleep disorder
- Enhance your understanding of how the entry of Pfizer and other new players will impact the insomnia market
- Identify the likely market positions of future drugs, such as indiplon and Estorra
| 
View Cart
